Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Empowering cancer care in Africa

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Latest in bladder cancer from the second half of 2025

Cancer control in India - Role of cancer registries

Do all hormone sensitive prostate cancers need triplet therapy?

Panel Discussion: Case based discussions muscle invasive bladder cancer

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety